MannKind (MNKD) Leerink Global Healthcare Conference 2026 summary

Strategic focus and business evolution

• Transitioned from a single-product company to a diversified portfolio through acquisitions and internal development, notably the scPharmaceuticals acquisition in Q4, which accelerated revenue diversification and integration efforts.

• Aims to outpace market expectations in 2026 with multiple growth drivers, including two FDA approvals and a phase II trial kickoff, alongside ongoing partner activities.

• Exclusive manufacturing rights for Tyvaso secured, stabilizing collaboration and service revenue streams, while shifting focus to higher-margin, controllable revenue sources.

• Revenue mix is shifting, with 70% expected to be under direct control by year-end, driven by Afrezza, FUROSCIX®, and pipeline programs.

• Strategic focus on accelerating trial enrollments, pediatric launches, and rapid execution of new product introductions.

Product and revenue growth drivers

• FUROSCIX® is positioned for significant growth, targeting both community physicians and hospital segments, with the auto-injector expected to expand market reach and reduce costs.

• Q4 saw FUROSCIX® revenues reach $23 million, with expectations of $110–$120 million for the year, excluding potential upside from the auto-injector launch.

• Increased field rep investment is expected to yield a productivity ramp in Q2, setting up further growth in Q3–Q4 as awareness and adoption increase.

• The auto-injector could rapidly convert patients from the on-body infuser, with a potential 70% reduction in COGS, significantly improving margins.

• Competitive landscape is evolving, but the focus remains on broadening awareness and offering multiple delivery platforms to meet diverse patient needs.

Afrezza and pediatric launch

• Shifted Afrezza from profitability to growth mode, leveraging positive pediatric data and recent label changes that double the starting dose without increasing hypoglycemia risk.

• ADA guidelines now place Afrezza on par with pumps and multiple daily injections, supporting payer discussions and market access.

• Market research suggests a 20–30% pediatric market share is possible, translating to $300–$500 million in future revenue.

• Launch strategy emphasizes a frictionless experience for children and caregivers, with investments in hiring and consumer outreach.